Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients

Inclusion Criteria: * Diagnosis of type 2 diabetes based on WHO criteria * Age 18-75 years old * Serum creatinine ≤ 1.5 mg/dL (130umol/L) * Albuminuria defined by a urine albumin/creatinine ratio(ACR) according to ADA criteria 2009 (microalbuminuria by 30-299 ug albumin/mg creatinine and macroalbuminuria by ≥300 ug albumin/mg creatinine on random spot urine collection ) * Continued stable seated systolic blood pressure \< 180 mmHg and diastolic blood pressure \< 110 mmHg * Willing to change antihypertensive medication regimen if necessary * Willing to provide written informed consent to participate in the study * Willing to take contraception,or infertility for the duration of the study Exclusion Criteria: * Type 1 diabetes mellitus * Present acute diabetic complication, or severe chronic diabetic complication(e.g. proliferative diabetic retinopathy) * Complicating uncontrolled severe infection * Hepatic insufficiency or renal insufficiency or severe disturbance of lipid metabolism * Blood pressure ≥ 180/110mmHg * Severe concomitant systemic disease(e.g. cardiac insufficiency, stroke), anticipated to be unable to finish the trial * Uncooperative,unable to follow up, or anticipated unable to finish the trial * Patients with other known specific renal diseases * Untreated urinary tract infection that would impact urinary protein values * Evidence of hepatic dysfunction including total bilirubin \> 2.0 mg/dL (34 mmol/L) or elevated transaminases * History of Cardiovascular disease as follows: Unstable angina pectoris, myocardial infarction, transient ischemic attack, cerebrovascular accident, New York Heart Association Functional Class III or IV heart failure, obstructive valvular heart disease or hypertrophic cardiomyopathy * Any risk of bleeding, or platelet count \< 100×109/L or anticipated surgery within research period * Active, recurrent or metastatic cancer, or known HIV infection * Participant in any experimental drug study in the past 90 days prior to the enrollment of the study, or plan to participate in any drug study during the study period * Prior exposure to sulodexide, either in a clinical setting or as a participant in another clinical study * Known allergy or intolerance to any heparin-like compounds or multiple drug allergies * Lactation, pregnancy, or an anticipated or planned pregnancy during the study period * Inability to give an informed consent or to cooperate with researchers (e.g. psychiatric disorder) or history of noncompliance to medical regimen